Canaccord keeps USD 132 target for BioNTech stock

Published on 10/24/2026 at 20:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech reports results on November 3, 2026. BioNTech stock costs EUR 78.65 on October 24, 2026, 0.19 percent below Xetra close.

Analyst target and reporting date

Canaccord Genuity maintained a USD 132.00 target on October 23, 2026.
Second-quarter 2026 revenue was EUR 105.60 million, down from EUR 260.80 million.
BioNTech stock costs EUR 78.65 at Lang & Schwarz on October 24, 2026, 0.19 percent below the Xetra close of October 23, 2026.
Third-quarter 2026 results are scheduled for November 3, 2026.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE (US09075V1026) carries a USD 132.00 price target after Canaccord Genuity maintained its Buy rating on October 23, 2026, according to Markets Insider. The stock was trading at EUR 78.65 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, 0.19 percent below the Xetra close of October 23, 2026 at EUR 78.80.

Revenue remains the central test

BioNTech's second-quarter 2026 revenue was EUR 105.60 million, compared with EUR 260.80 million in the second quarter of 2025. The 59.51 percent decline was primarily driven by lower demand for COVID-19 vaccines, according to the company's financial release filed with the SEC on August 4, 2026.

The same release reported an IFRS net loss of EUR 820.80 million for the quarter, compared with EUR 386.60 million a year earlier. Diluted loss per share widened to EUR 3.24 from EUR 1.60, while operating cash flow was positive at EUR 10.50 million.

Nasdaq range frames the price

BioNTech's Nasdaq quote was last at USD 88.11 on October 23, 2026 at 4:00 p.m. ET. Its 52-week range was USD 79.52 to USD 124.00, placing the latest US quote USD 8.59 above the low and USD 35.89 below the high. Market capitalization stood at USD 22.1 billion on that date.

What does November 3 add?

BioNTech will publish third-quarter 2026 results on November 3, 2026, with a corporate update and investor webcast, as stated in the company's release dated October 20, 2026, BioNTech. That date gives investors the next scheduled test of the revised 2026 revenue outlook of EUR 1.60 billion to EUR 1.90 billion.

BioNTech and its peers

Moderna was last at USD 200.10 on October 23, 2026, down 1.25 percent, with a market capitalization of USD 79.9 billion. Pfizer was last at USD 30.03 on the same date, down 1.28 percent, with a market capitalization of USD 171.2 billion.

Price and reporting date

Canaccord's USD 132.00 target and the November 3, 2026 reporting date give BioNTech stock two clearly dated reference points, while the latest quarterly figures show the scale of the revenue reset. The stock was trading at EUR 78.65 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, 0.19 percent below the Xetra close of October 23, 2026 at EUR 78.80. The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.